SG11201908825TA - Stable multispecific antibodies - Google Patents

Stable multispecific antibodies

Info

Publication number
SG11201908825TA
SG11201908825TA SG11201908825TA SG11201908825TA SG 11201908825T A SG11201908825T A SG 11201908825TA SG 11201908825T A SG11201908825T A SG 11201908825TA SG 11201908825T A SG11201908825T A SG 11201908825TA
Authority
SG
Singapore
Prior art keywords
international
paris
pct
fremiet
avenue
Prior art date
Application number
Inventor
Eugene Zhukovsky
Olivier Leger
Richard J Morse
Original Assignee
Biomunex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomunex Pharmaceuticals filed Critical Biomunex Pharmaceuticals
Publication of SG11201908825TA publication Critical patent/SG11201908825TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT O V SID o mita Hon Imo VII IE (10) International Publication Number WO 2018/178101 Al (51) International Patent Classification: C07K 16/46 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/057819 (22) International Filing Date: 27 March 2018 (27.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305353.9 27 March 2017 (27.03.2017) EP (71) Applicant: BIOMUNEX PHARMACEUTICALS [FR/FR]; 113 me de la Tour, 75116 PARIS (FR). (72) Inventors: ZHUKOVSKY, Eugene; 5 avenue Fremiet, 75016 Paris (FR). LEGER, Olivier; 603 Route des Luches, 74800 Saint Sixt (FR). MORSE, Richard J.; 5 avenue Fremiet, 75016 Paris (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) O — with sequence listing part of description (Rule 5.2(a)) 00 1-1 N 1-1 00 (54) Title: STABLE MULTISPECIFIC ANTIBODIES 0 (57) : The invention relates to multispecific antibody constructs comprising Fab fragments having particular set of mutations \" at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.
SG11201908825T 2017-03-27 2018-03-27 Stable multispecific antibodies SG11201908825TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305353 2017-03-27
PCT/EP2018/057819 WO2018178101A1 (en) 2017-03-27 2018-03-27 Stable multispecific antibodies

Publications (1)

Publication Number Publication Date
SG11201908825TA true SG11201908825TA (en) 2019-10-30

Family

ID=58701560

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908825T SG11201908825TA (en) 2017-03-27 2018-03-27 Stable multispecific antibodies

Country Status (13)

Country Link
US (1) US11560437B2 (en)
EP (1) EP3601366A1 (en)
JP (2) JP7432365B2 (en)
KR (1) KR20190141154A (en)
CN (1) CN111094355A (en)
AU (1) AU2018241881A1 (en)
BR (1) BR112019019998A2 (en)
CA (1) CA3057567A1 (en)
IL (1) IL269559B1 (en)
MX (1) MX2019011585A (en)
SG (1) SG11201908825TA (en)
WO (1) WO2018178101A1 (en)
ZA (1) ZA201906981B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3433273T3 (en) 2016-03-25 2022-02-14 Biomunex Pharmaceuticals BINDING OF MOLECULES TO CD38 AND PD-L1
CN109563166B (en) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 Bispecific antibodies targeting EGFR and HER2
CN110520444A (en) 2017-01-09 2019-11-29 拜奥穆尼克斯制药 It is used to prepare the peptide linker of multi-specificity antibody
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
US20240010754A1 (en) * 2020-12-03 2024-01-11 Jiangsu Hengrui Medicine Co., Ltd. Multispecific antigen binding protein
CN114106192A (en) * 2021-12-20 2022-03-01 广州爱思迈生物医药科技有限公司 Bispecific antibodies and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
LT2857516T (en) 2000-04-11 2017-09-11 Genentech, Inc. Multivalent antibodies and uses therefor
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
MX358752B (en) 2011-03-25 2018-08-31 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins.
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
ES2732712T3 (en) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US10047163B2 (en) * 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
EP3176185A1 (en) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
EP3068430A4 (en) * 2013-11-13 2017-07-05 Zymeworks Inc. Methods using monovalent antigen binding constructs targeting her2
RS59907B1 (en) 2014-03-28 2020-03-31 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
EP3143043B1 (en) 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
CN107108738A (en) 2014-07-25 2017-08-29 西托姆克斯治疗公司 Anti-cd 3 antibodies, it anti-cd 3 antibodies, polyspecific anti-cd 3 antibodies, polyspecific can be activated can activate anti-cd 3 antibodies and its application method
GB201414823D0 (en) * 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
DK3433273T3 (en) 2016-03-25 2022-02-14 Biomunex Pharmaceuticals BINDING OF MOLECULES TO CD38 AND PD-L1
CN109563166B (en) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 Bispecific antibodies targeting EGFR and HER2
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN110520444A (en) 2017-01-09 2019-11-29 拜奥穆尼克斯制药 It is used to prepare the peptide linker of multi-specificity antibody
CN111133003B (en) 2017-09-22 2024-01-12 上海药明生物技术有限公司 Novel bispecific polypeptide complexes
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
MX2019011585A (en) 2020-02-17
RU2019134211A3 (en) 2021-06-11
AU2018241881A1 (en) 2019-11-07
BR112019019998A2 (en) 2020-04-28
JP2020515253A (en) 2020-05-28
CN111094355A (en) 2020-05-01
CA3057567A1 (en) 2018-10-04
US20200299413A1 (en) 2020-09-24
JP7432365B2 (en) 2024-02-16
US11560437B2 (en) 2023-01-24
IL269559A (en) 2019-11-28
JP2023175760A (en) 2023-12-12
IL269559B1 (en) 2024-02-01
WO2018178101A1 (en) 2018-10-04
EP3601366A1 (en) 2020-02-05
KR20190141154A (en) 2019-12-23
RU2019134211A (en) 2021-04-28
ZA201906981B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
SG11201908825TA (en) Stable multispecific antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201909011PA (en) Niraparib compositions
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201811550XA (en) Demand prediction for time-expiring inventory
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201909807TA (en) Methods of manufacturing of niraparib